For Heart Health, Consider Statins
There are old notions still being bandied about that statins are dangerous to the liver. This is completely untrue. Statins pose no danger to the human liver and in fact are safer than recommended doses of acetaminophen, which most people know as Tylenol.
Statins can in 10 to 15% of individuals cause muscle achiness, and certain statins are worse than others in this regard. Lovastatin and simvastatin, two of the earliest available statins, have the highest rates of muscle-related complaints. This is likely because they “compete” for metabolism with many other drugs, causing elevated blood levels of these two statins. Supplementing vitamin D will often ease statin—associated muscle aches. A naturally occurring antioxidant known as Coenzyme Q10 or CoQ10, which is often taken for this purpose, has never been shown in a clinical study to be effective.
Statins can increase the tendency for a given individual to become diabetic. However, this is generally in those who are at high risk for diabetes and are already pre-diabetic. In fact, it is likely that statins simply “move up the date” of the diagnosis of diabetes, and the actual effect on blood sugars is quite mild. And, in an odd coincidence, no group derives more benefit from taking statins, in terms of prevention of heart attack and death from heart attack, than those with diabetes. Virtually all individuals with diabetes over 40 years of age should in fact take a statin.
Diabetics of course, are not the only group that benefits from statins. In people who already have suffered heart attacks, statins cut the risk of a second attack nearly in half. Stroke risk is reduced with statin therapy as well, both in those who’ve already had a stroke, and those with no such history.
The American Heart Association and the American College of Cardiology recommend that, among adults aged 40 and older with no prior history of heart attack or stroke, the 10-year “projected risk” of such an event be calculated. This can be done during an office visit to your health care provider. Any individual with a 10-year predicted risk of 7.5% or higher, it is recommended, should then be placed on a statin, to prevent the first occurrence of heart attack or stroke.
So, it appears that, in sum, the benefits of taking statins far outweighs the bad. Talk to your health care provider about whether or not a statin may be right for you. And if one is prescribed, by all means, take it.
Dr. Scott Shurmur is a cardiologist at the Texas Tech Physicians Center for Cardiovascular Health and chief of cardiology at Texas Tech University Health Sciences Center.
Related Stories
Molecular Pathology Preceptorship: Unmatched Value and Experience
Ericka Hendrix, PhD, MB(ASCP)CM, Program Director and Associate Professor in the Master of Science in Molecular Pathology program in the School of Health Professions spoke about the program’s preceptorship.
Moseley Named Permian Basin Regional Dean of the Texas Tech University Health Sciences Center School of Nursing
Kelly Moseley, DHSc, R.N., has been named the TTUHSC School of Nursing regional dean in the Permian Basin.
TTUHSC School of Nursing to Celebrate New YWCA Location
Community members in central Lubbock now have access to health care services and prenatal programs at one location inside the YWCA.
Recent Stories
U.S. News & World Report Ranks TTUHSC Schools Among Best for 2025 Graduate School Rankings
Several graduate programs at TTUHSC have been recognized in the 2025 U.S. News & World Report Best Graduate School Rankings, reaffirming the university’s continued excellence in health sciences education and training.
TTUHSC Jerry H. Hodge School of Pharmacy Students Celebrate Residency Assignments on Match Day
Fourth-year Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy students interested in completing a residency after they graduate in May have learned where they will spend the next stage of their training during Pharmacy Residency Match Day.
TTUHSC Researchers Seek Novel Therapies for Chronic Pain
The National Institute of Neurological Disorders and Stroke at the NIH recently awarded a $1.94 million grant to Mahmoud Salama Ahmed, Ph.D., and his project team from the Department of Pharmaceutical Sciences at TTUHSC. Jerry H. Hodge School of Pharmacy.